The FDA has approved a new starting dosage regimen for the subcutaneous formulation of lecanemab-irmb (Leqembi), allowing patients to begin treatment at home under their own care or that of a caregiver. This marks the first time this Alzheimer’s treatment can be administered outside of a clinical setting. The agency’s action expands access for individuals with early-stage disease who have confirmed amyloid buildup in their brains.
Lecanemab targets beta-amyloid proteins in the brain, a hallmark of Alzheimer’s disease pathology. The medication removes these proteins, which researchers believe contribute to the progression of cognitive decline. While the drug does not restore lost memories or reverse damage, it has been shown to slow the rate of cognitive and functional decline over time. This distinction is important for setting realistic expectations for patients and families.
The approval builds on existing use of the drug, which was first authorized in 2023 for early Alzheimer’s. In January 2025, the agency approved maintenance dosing every four weeks. The new subcutaneous option replaces the traditional intravenous infusions required for that maintenance phase and now also applies to the initial loading dose.
Clinical trial results
Two randomized, placebo-controlled trials provided the data supporting this regulatory decision. In Study 1, which enrolled 854 participants, the primary 12-month end point was not met, but treatment benefits became evident by the 18-month mark. Participants receiving the drug showed a significant reduction in brain amyloid burden and slower cognitive decline across multiple measures, including ADAS-Cog14 and the CDR-SB.
Related: User Receives Unexpected Block Notification
Study 2, known as Clarity AD, enrolled 1,795 participants and successfully met its primary end point. The results showed significantly less clinical decline compared to placebo on the CDR-SB scale after 18 months. The drug also produced statistically significant improvements on other assessments of cognition and function. Common adverse events included infusion-related reactions and amyloid-related imaging abnormalities with edema or effusion (ARIA-E).
Real-world data from the trials suggests the benefits of the treatment may emerge later than initially projected, a pattern seen in some disease-modifying therapies. This timeline requires patience from both prescribers and patients, as the clinical impact of reducing amyloid plaques does not manifest immediately after the first dose. Monitoring for side effects remains a standard part of the protocol.
Important safety considerations
Healthcare providers must adhere to specific guidelines when prescribing this medication. The FDA notes that lecanemab is contraindicated for patients with serious hypersensitivity to the drug or its inactive ingredients. Doctors should exercise caution when considering the treatment for individuals taking anticoagulants or those with other risk factors for intracerebral hemorrhage.